A systematic review and meta-analysis of effectiveness and safety of therapy for overactive bladder using botulinum toxin A at different dosages
Metrics: PDF 688 views | HTML 1313 views | ?
Hui-Yun Gu1,*, Ju-Kun Song2,*, Wen-Jun Zhang3, Jin Xie4, Qi-Sheng Yao5, Wen-Jing Zeng6, Chao Zhang1 and Yu-Ming Niu1,5
1Center for Evidence-Based Medicine and Clinical Research, Taihe Hospital, Hubei University of Medicine, Shiyan 442000, China
2Department of Oral and Maxillary Surgery, Guizhou Provincial People's Hospital, Guiyang 550002, China
3Department of Ultrasound, Taihe Hospital, Hubei University of Medicine, Shiyan 442000, China
4Administrative Office, Taihe Hospital, Hubei University of Medicine, Shiyan 442000, China
5Department of Urinary Surgery, Taihe Hospital, Hubei University of Medicine, Shiyan 442000, China
6Department of Anesthesiology, Taihe Hospital, Hubei University of Medicine, Shiyan 442000, China
*Co first authors
Chao Zhang, email: email@example.com
Yu-Ming Niu, email: firstname.lastname@example.org
Keywords: overactive bladder, botulinum toxin A, urinary incontinence, incontinence quality of life, meta-analysis
Received: June 04, 2017 Accepted: July 25, 2017 Published: August 07, 2017
Purpose: To assess the effectiveness and safety of botulinum toxin A (BTX-A) at different dosages for overactive bladder (OAB).
Materials and Methods: The MEDLINE, EMBASE, and Cochrane Controlled Trials Register databases were searched through November 3, 2016 to identify relevant randomized controlled trials (RCTs).
Results: Eleven studies were identified in this meta-analysis. Compared with placebo, the urinary incontinence (UI) episodes per week as the primary outcomes, urodynamic parameters including maximum cystometric capacity (MCC), and maximum detrusor pressure (MDP) for neurogenic detrusor overactivity (NDO) at 6 weeks, and for idiopathic detrusor overactivity (IDO) at 36 weeks were evaluated. These and other outcomes for effectiveness of BTX-A at different dosages in two observation periods indicate that a dose greater than 50 U is significantly more effective for certain symptoms of OAB compared with placebo. However, there were no significant differences between some dosages. Compared with placebo, the outcomes of total adverse events for NDO and for IDO show that doses of 300 U and 200 U for NDO are associated with more complications.
Conclusions: In consideration that the treatments of BTX-A were with minimal, local, and manageable adverse effects, this meta-analysis demonstrates that BTX-A 200 U is recommended for management of NDO for short-term treatment for there was no significant difference from the larger dose of 300U. The short-term efficacies of BTX-A for IDO remain to be investigated.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.